Yahoo Web Search

Search results

1. • Understanding the immune system's 'big eater': New insights into macrophage behavior in cancer...

     Medical Xpress· 12 hours ago

     The study, titled "Antibody surface mobility amplifies Fc gammaR signaling via Arp2/3 during phagocytosis," was published in the Biophysical Journal.

2. • Antibody discovery promises new hope in influenza B battle, paves way for universal vaccine

     Medical Xpress· 7 days ago

     Seasonal flu vaccines cover influenza B and the more common influenza A but do not stimulate the broadest possible range of immune responses against both viruses. In addition, people whose immune ...

3. • 

     Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

     Zacks via Yahoo Finance· 12 hours ago

     Pipeline Updates Prothena is evaluating PRX012 — a wholly-owned investigational next-generation...

4. • 

     AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

     Zacks via Yahoo Finance· 1 day ago

     The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with...

5. • ... Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results,...

     The Woonsocket Call· 5 days ago

     After rigorous evaluation by Scientific Program Committee and ASCO Leadership, LBL-024, a bispecific antibody independently developed by Leads Biolabs with global intellectual ...

6. • For Statutory Equivalents, Even One Means May Be Enough

     The National Law Review· 1 day ago

     A US Patent & Trademark Office (PTO) appeals review panel decided that a means-plus-function (M+F) claim element supported by the disclosure of only a single species is not invalid for indefiniteness ...

7. • ...Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1...

     Benzinga· 6 days ago

     Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate ("ADC"), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt,

8. • Small Business - Picayune Item | Picayune Item

     The Picayune Item· 5 days ago

     Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today ...

9. • 

     ...Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment...

     KOIN News 6 Portland· 5 days ago

     ...biopharmaceutical company that develops, manufactures and commercializes high-quality medicines...

10. • 

      Alchemab receives grant to advance promising antibody for Parkinson’s disease

      BioPharma-Reporter· 2 days ago

      The grant, part of MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, aims to support...